Matrix metalloproteinases and cardiovascular disease

European Heart Journal

Volumn 27, Issue 2, 2006, Pages 121-122

  Agewall, Stefan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GLYCERYL TRINITRATE; LOSARTAN; MATRIX METALLOPROTEINASE;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

CARDIOVASCULAR DISEASES; HUMANS; MATRIX METALLOPROTEINASES;

EID: 30344435917     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi639     Document Type: Editorial

References (11)

1. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
2. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998;3:199-206.
3. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-2131.
4. Ravn HB, Falk E. Histopathology of plaque rupture. Cardiol Clin 1999;17:263-270.
5. Ardans JA, Blum A, Mangan PR, Wientroub S, Cannon RO III, Wahl LM. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arteriosder Thromb Vasc Biol 2001; 21: 1265-1268.
6. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
7. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-217.
8. Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, Cambien F, Tiret L, Münzel T, Blankenberg S. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006;27:150-156. First published on October 17, 2005, doi:10.1093/eurheartj/ ehi582.
9. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-585.
10. Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, Watanabe T, Komatsubara I, Kondo J, Tsuji T. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78:278-284.
11. Death AK, Nakhla S, McGrath KC, Martell S, Yue DK, Jessup W, Celermajer DS. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol 2002;39:1943-1950.